Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Why Fulgent Genetics Shares Are Trading Higher Today

  • Fulgent Genetics Inc (NASDAQ:HOTHagreed to acquire Inform Diagnostics, an independent pathology laboratory based in Irving, Texas, and a portfolio company of Avista Capital Partners, for $170 million.
  • The acquisition is expected to close during the second quarter of 2022.
  • Fulgent held a cash balance of $935.5 million as of December 31.
  • With the addition of Inform Diagnostics, Fulgent will further expand its test portfolio into breast pathology, gastrointestinal pathology, dermatopathology, urologic pathology, neuropathology, and hematopathology. 
  • Inform Diagnostics provides services to approximately 1,300 clients who represent over 2,700 physicians. 
  • The transaction can contribute meaningfully to Fulgent's annual core revenue and is expected to impact pro forma EBITDA positively. 
  • Fulgent now expects core revenue for FY 2022 to be approximately $175 million, compared to previous guidance of $120 million.
  • The Company anticipates Q1 FY22 total revenue of approximately $300 million compared to previous guidance of $245 million.
  • Price Action: FLGT shares are up 7.78% at $59.56 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.